Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epitope

This article was originally published in The Gray Sheet

Executive Summary

Receives $8.1 mil. from private placement with European investors, in which it issued 2.9 mil. warrants to purchase Epitope common stock at $14.875 per share. The warrants are set to expire 120 days after FDA approves Epitope's OraSure oral specimen collection device for HIV-1 screening, or 120 days after "the average sales price of Epitope common stock has been at least $30 for 20 consecutive trading days," or by Dec. 23, 1997. If the warrants are exercised, Epitope could receive up to $40 mil. At a Dec. 18 meeting, FDA's blood products advisory panel was unable to reach a consensus on the approvability of Epitope's PMA for Orasure ("The Gray Sheet" Dec. 21, p. 5)....
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel